Blueprint Medicines ups full year revenue guidance

 -- Achieved 61% year-over-year growth with $149.4 million in AYVAKIT net product revenues in the first quarter 2025 --

-- Raising AYVAKIT net product revenue guidance to $700 - $720 million for 2025 --

--  Initiated BLU-808 proof of concept studies in allergic rhinoconjunctivitis and chronic urticaria –

https://www.prnewswire.com/news-releases/blueprint-medicines-reports-first-quarter-2025-results-and-raises-ayvakitayvakyt-avapritinib-full-year-revenue-guidance-302443541.html